ArticleCureus2025
COVID-19-Associated Severe Aplastic Anemia in an 18-Month-Old Child: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has significantly impacted global health since its emergence in late 2019. Established evidence indicates an increasing incidence of hematologic abnormalities caused by COVID-19, such as aplastic anemia. Only a few pediatric cases have been reported. We present a previously healthy 18-month-old boy with fever, cough, diarrhea, rash, and ear discharge for one week. He was febrile, tachycardic, drowsy, with bilateral purulent ear discharge, petechiae, and cervical lymphadenopathy. Blood tests showed severe pancytopenia with high inflammatory markers, and SARS-CoV-2 PCR was positive. Bone marrow biopsy revealed severe aplastic anemia (<10% cellularity), and genetic testing excluded inherited causes. He was treated with blood transfusions and romiplostim. After one year of supportive management, the patient showed a partial response and improving counts, so bone marrow transplantation was deferred, with continued monitoring for sustained hematologic recovery or relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.